SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Shares of MLTX are trending amid a steep decline following mixed results from a Phase 3 trial, leading to significant community discussion around potential short covering and whether the market has overreacted. Some investors are speculating about a possible acquisition by Merck, while others are assessing the company's cash reserves and future prospects. The conversation highlights the volatile nature of biotech stocks and the high-risk, high-reward potential in the sector.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

APDN is trending following news of a $58M private placement to initiate a BNB-focused digital asset strategy, with plans to change its ticker to BNBX; the stock experienced multiple trading halts as a result. The community is discussing the potential for a significant price increase, with some drawing comparisons to other low-float runners and noting Scaramucci's involvement as an advisor. This activity occurs amid broader speculation about the company's strategic shift towards digital assets.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals ($AUPH) is trending due to an ex-FDA employee's LinkedIn post questioning the safety and efficacy of their drug Lupkynis, sparking concerns about potential market manipulation. The community is debating the validity of the claims, the company's response, and possible legal action. Some investors believe this is a strategic move to lower the price before a buyout, while others worry about the drug's reputation and future sales.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood ($HOOD) is trending as it reached new all-time highs, driven by optimism around its prediction markets business and expansion into new fintech services. Community members are actively discussing the stock's potential to continue its impressive run, while some caution against overvaluation and a possible pullback. Bullish sentiment is fueled by strong financials and the stock's inclusion in the S&P 500.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending as investors eagerly anticipate the release of its Preliminary Feasibility Study (PFS), with some speculating its imminent arrival could trigger a significant price surge. Bullish sentiment is fueled by increasing volume, government backing, and potential short squeezes, while community members express excitement about the company's long-term prospects in the lithium and battery recycling sectors.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a 'culture coin' and a way to invest in the cannabis space. Community members are drawn to its focus on freedom, community, and growth, viewing it as more than just a token. Bullish sentiment is also fueled by broader discussions around potential cannabis legalization.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is gaining traction as an AI-themed memecoin associated with Elon Musk's Grok AI, with the community rallying behind its potential. Some are pointing to a tight float and potential catalyst related to NXXT, while others highlight the strong community and growing number of holders. It is also being mentioned in the context of other trending coins like $UPDOG.X and $RAGE.X.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding Limited is trending amid high volatility, with community members debating whether it's primed for another surge or a pullback. Discussions revolve around its low float and potential for a short squeeze, while some caution against the risks associated with Chinese stocks. The stock's recent price action and potential technical patterns are also being closely watched by traders.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as the stock experiences notable price volatility, prompting discussions around potential bottom fishing and averaging down strategies among investors. Recent news of the COO's departure appears to be weighing on the stock, while some community members see a disconnect between the stock price and the company's fundamentals, citing solid growth and good earnings. Broader market sentiment around fast-casual restaurants and consumer spending is also influencing the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses its potential to reclaim higher price levels, with some anticipating ETF approvals could act as a catalyst. Chatter includes discussion of meme coins built on the Solana blockchain and the overall bullish sentiment for "Uptober". Technical analysis suggests $SOL.X is showing signs of strength after bouncing off a key Fibonacci retracement level.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HCW Biologics shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster.The stock jumped 60.8% to $5.55 on Monday, marking its best session since May 13, before adding another 0.5% in after-hours trading.The Florida-based biotech firm said it has developed an advanced form of pembrolizumab, which is sold by Merck as Keytruda and is considered the world’s top-selling FDA-approved immune checkpoint inhibitor.Drugs in this class are designed to help the immune system fight cancer, but they often only work for a small percentage of patients, and results are not always long-lasting.HCW Biologics said its version aims to go a step further: not only releasing the “brake” on the immune system but also activating immune cells and helping them infiltrate solid tumors, such as those seen in pancreatic and ovarian cancer.&nbsp;In early lab studies and mouse models, the company states that the therapy demonstrated stronger results than Keytruda alone, at dose levels that were well tolerated.CEO Hing C. Wong noted that global sales of checkpoint inhibitors topped $40 billion in 2024, underscoring the commercial potential if effectiveness can be improved.The company also sees potential for its therapy beyond cancer. HCW Biologics said checkpoint inhibitors may help clear “senescent” cells, which are aged cells that no longer divide but drive inflammation, making them a possible tool against age-related diseases.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 538% surge in 24-hour message volume, placing it among the most trending stocks on the platform.One user noted they had already taken profits, saying they made money on $HCWB and estimated early buyers likely gained 20–30%.<stembedurl>https://stocktwits.com/Camelinvesting/message/626495258</stembedurl>Another user praised HCW Biologics’ research, suggesting that since immune checkpoint inhibitors have shown success, improving on them could be the right path forward.<stembedurl>https://stocktwits.com/everything5/message/626494404</stembedurl><a href="https://stocktwits.com/symbol/HCWB">HCW Biologics’ stock</a> has declined 68.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCW Biologics (HCWB) shares logged their best session in over three months on Monday after the firm revealed progress with a new cancer drug it thinks could be a multi-billion-dollar blockbuster. | Image source: Getty Images

HCW Biologics Stock Scores Biggest Gain Since May As Cancer Drug Breakthrough Fuels Blockbuster Hopes

The biotech firm said its next-generation version of Keytruda showed stronger results in early studies and could eventually expand into both cancer and age-related disease treatments.

Equity

Why Is Penny Stock HCW Biologics Surging On Monday?

Why Is Penny Stock HCW Biologics Surging On Monday...

HCW Biologics' stock rises as it partners with WY Biotech in an exclusive global license deal, securing $7 milion upfront and future potential milestone payments.
read more...

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics ) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...

Comparing HCW Biologics (NASDAQ:HCWB) and Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA  Get Free Report) and HCW Biologics (NASDAQ:HCWB  Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the...

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

HCW Biologics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$3.84
Prev Close	$4.09
Open	$4.01
Dividend Yield	0.00%
50-Day Moving Average	$4.39
Beta	0.13
Avg. Volume	4.32M
PE Ratio	-0.25

52-Week High	$100.80
52-Week Low	$2.77
Market Capitalization	$8.8M
EPS (Annual)	-$30.96
Price to Book	-168.94
Revenue Per Employee	$71,299.78
Enterprise Value/EBITDA	N/A

HCWB
HCW Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HCWB News

HCWB HCW Biologics Inc